Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Human growth hormone stabilizes walking and improves strength in a patient with dominantly inherited calpainopathy

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Results of an open label feasibility study of sodium valproate in people with McArdle disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Contractile properties are impaired in congenital myopathies

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. No effect of oral sucrose or IV glucose during exercise in phosphorylase b kinase deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. 242nd ENMC International Workshop: Diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1-3 March 2019

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Determining minimal important change for the thyroid-related quality of life questionnaire ThyPRO

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Incidence and Clinical Presentation of Pheochromocytoma and Sympathetic Paraganglioma: A Population-based Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The aim was to investigate if daily low-dose treatment with recombinant human growth hormone (somatropine) can stabilize or improve muscle strength and walking capability in a patient with dominantly inherited calpainopathy. The patient was treated with daily injections of somatropine, except for a 6-month pause, over a period of 4.5 years. Efficacy was assessed by repeated muscle dynamometry tests and 6-minute walk tests (6MWT). Strength improved in most muscle groups on treatment, deteriorated in the 6-month off treatment, and improved again when treatment was resumed. The 6MWT stabilized during the initial 18-month treatment period, then deteriorated in the 6 months off treatment and improved to pre-trial levels when treatment was resumed. The findings suggest that supplementation with somatropine, within physiological ranges, may improve muscle strength and stabilize walking capability in a patient with calpainopathy. This finding calls for testing of somatropine supplementation in muscular dystrophies in a randomized study.

Original languageEnglish
JournalNeuromuscular disorders : NMD
Volume27
Issue number4
Pages (from-to)358-362
Number of pages5
ISSN0960-8966
DOIs
Publication statusPublished - Apr 2017

    Research areas

  • Journal Article

ID: 51549592